The PLAC Test for Lp-PLA2 Activity is an FDA-cleared test that aids in predicting risk for CHD in patients with no prior history of cardiovascular events. The PLAC Test for Lp-PLA2 Activity provides physicians with additional prognostic information that was previously unavailable with traditional risk factors.

Assessing patients’ risk for CHD events remains a challenge in primary prevention

  • Patients with low and moderate CHD risk still have a significant risk for events over 10 years1
  • 50% of myocardial infarctions occur in individuals with normal LDL2
  • When assessing CHD risk, cholesterol testing alone is not always enough3

Event risk prediction with the PLAC Test for Lp-PLA2 Activity

  • Novel risk prediction for CHD in patients with no prior history of cardiovascular events
  • Prognostic value independent of standard lipid profile testing
  • Use in conjunction with clinical evaluation and patient risk assessment
  • Incorporates a validated and easy-to-use cut point of 225 nmol/min/mL

Demonstrated across multiple clinical trials and patient populations

  • The greater the Lp-PLA2 activity, the greater the risk for fatal and nonfatal CHD events (Figure 1)
  • PLAC activity above 225 nmol/min/mL identifies patients at increased risk for CHD events across patient type and population (Figure 2)
  • Absolute risk for CHD events is 2.1 times greater with a positive PLAC Test (Figure 2)
Lp-PLA2 activity and CHD* risk4
Positive correlation between Lp-PLA2 activity and risk for coronary heart disease
* Fatal and nonfatal events.
Figure 1
Risk for CHD events by patient type5
Increased absolute risk for certain sub-populations
Figure 2

The REGARDS multicenter study and the PLAC Test for Lp-PLA2 Activity

  • One of the largest National Institutes of Health (NIH) studies ever undertaken, with over 30,000 patients enrolled across the United States
  • The Lp-PLA2 substudy examined 4,598 case-matched patients
  • A cut point of 225 nmol/min/mL was prospectively assigned based on prior studies and publications
  • In a REGARDS multicenter substudy, high Lp-PLA2 activity was more closely associated with outcome than high low-density lipoprotein cholesterol (LDL) and low high-density lipoprotein cholesterol (HDL). Only status of diabetes or smoking was more closely associated with events (Table 1)
REasons for Geographic and Racial Differences in Stroke.
Hazard ratio (HR) by risk factor6
Lp-PLA2 is third-highest risk factor for CHD events (behind diabetes and current smoking)
Table 1

The PLAC Test for Lp-PLA2 Activity is clearly associated with CHD event risk end points

  • Patients with positive PLAC activity are at high risk for first-time myocardial infarction, cardiac revascularization, and cardiac death (Table 2)
  • At the cut point of 225 nmol/min/mL, the primary composite end point of risk for CHD events was reached (Figure 3)
  • The cut point of 225 nmol/min/mL achieved statistical significance for each individual risk component (Table 2)
PLAC activity prediction of CHD events5
PLAC test for Lp-PLA2 activity has predictive value for multiple CHD events
Table 2
Total CHD event rates5
As PLAC activity increases, so does risk for CHD events
Figure 3